AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037
01/06/2023 – AB Science today announced that the patent office of Canada has issued a Notice of Allowance (NOA) for a patent relating to methods of treating amyotrophic lateral sclerosis (ALS) with its lead compound masitinib